

Michael B Atkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9049169/publications.pdf>

Version: 2024-02-01

228
papers

54,255
citations

10986

71
h-index

2078

204
g-index

233
all docs

233
docs citations

233
times ranked

44956
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. <i>Melanoma Research</i> , 2022, 32, 35-44.	1.2	2
2	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. <i>Cancers</i> , 2022, 14, 644.	3.7	11
3	Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	1.3	0
4	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	7.1	75
5	Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. <i>Cancers</i> , 2022, 14, 1505.	3.7	1
6	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	1.6	33
7	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
8	Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy. <i>Future Oncology</i> , 2022, , .	2.4	4
9	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	1.6	40
10	Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 565-574.	2.4	1
11	Abstract 6130: Comprehensive genomic and transcriptomic profiling of acral lentiginous melanoma. <i>Cancer Research</i> , 2022, 82, 6130-6130.	0.9	0
12	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 454-489.	329.8	13
13	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 427-439.	1.9	15
14	The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 800-807.e1.	4.9	5
15	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	7.0	12
16	Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. <i>Cell</i> , 2022, 185, 2591-2608.e30.	28.9	62
17	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	1.9	64
18	Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. <i>Radiology</i> , 2021, 298, 332-340.	7.3	13

#	ARTICLE	IF	CITATIONS
19	Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. <i>Gastroenterology</i> , 2021, 160, 1359-1372.e13.	1.3	41
20	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	7.0	49
21	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
22	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	12.8	84
23	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	1.6	145
24	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. <i>European Journal of Cancer</i> , 2021, 145, 1-10.	2.8	17
25	Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities. <i>Journal of Immunotherapy</i> , 2021, 44, 198-203.	2.4	5
26	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	1.6	83
27	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	1.2	66
28	Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response. <i>Cancer Research</i> , 2021, 81, 3607-3620.	0.9	19
29	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	1.9	20
30	Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 541-549.	2.1	8
31	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e306-e312.	1.9	12
32	PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma. , 2021, 9, e002955.		8
33	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). <i>Melanoma Research</i> , 2021, 31, 67-75.	1.2	15
34	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	1.6	121
35	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	1.6	580
36	Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. , 2021, 7, .		16

#	ARTICLE	IF	CITATIONS
37	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	7.0	25
38	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14
39	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	10.7	129
40	DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 356154-356154.	1.6	90
41	Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> , 2021, 13, 6109.	3.7	9
42	Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women. <i>Annals of Behavioral Medicine</i> , 2020, 54, 1-9.	2.9	5
43	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	10.7	160
44	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	10.7	466
45	A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor. <i>Immunotherapy</i> , 2020, 12, 861-867.	2.0	4
46	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
47	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
48	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	1.9	20
49	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5598-5608.	7.0	13
50	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
51	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	16.8	262
52	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
53	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3088-3094.	1.6	61
54	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	7.0	27

#	ARTICLE	IF	CITATIONS
55	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 527-541.	3.3	36
56	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 37-51.	2.0	10
57	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	7.0	20
58	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
59	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	1.6	190
60	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	3.8	162
61	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5001-5001.	1.6	50
62	Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma. , 2020, , 1109-1140.		0
63	Identification of Patients with Immune-related Adverse Events from Clinical Notes using Machine Learning. , 2020, , .		0
64	A case of checkpoint inhibitor-induced celiac disease. , 2019, 7, 203.		25
65	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	7.1	388
66	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	1.6	52
67	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	7.0	80
68	Choice of first-line therapy in metastatic melanoma. <i>Cancer</i> , 2019, 125, 666-669.	4.1	12
69	Management of metastatic cutaneous melanoma: updates in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985166.	3.2	29
70	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , 2019, 393, 2404-2415.	13.7	778
71	YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells. <i>Developmental Cell</i> , 2019, 49, 425-443.e9.	7.0	78
72	Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2019, 11, 617-629.	2.0	29

#	ARTICLE	IF	CITATIONS
73	Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. , 2019, 7, 61.		40
74	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115.	27.0	1,824
75	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1116-1127.	27.0	2,319
76	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clinical Cancer Research, 2019, 25, 6098-6106.	7.0	14
77	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
78	Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. Melanoma Research, 2019, 29, 70-76.	1.2	9
79	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
80	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naïve patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. Quality of Life Research, 2019, 28, 109-119.	3.1	14
81	Clinical and economic outcomes associated with treatment sequences in patients with <i>BRAF</i>-mutant advanced melanoma. Immunotherapy, 2019, 11, 283-295.	2.0	24
82	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. Journal of Clinical Oncology, 2019, 37, 4500-4500.	1.6	85
83	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. Journal of Clinical Oncology, 2019, 37, 4512-4512.	1.6	30
84	Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4515-4515.	1.6	3
85	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-ê clear cell renal cell carcinoma (NCC-RCC).. Journal of Clinical Oncology, 2019, 37, 4569-4569.	1.6	23
86	Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.. Journal of Clinical Oncology, 2019, 37, 9533-9533.	1.6	2
87	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.. Journal of Clinical Oncology, 2019, 37, 546-546.	1.6	42
88	Cytokines (IL-2, IFN GM-CSF etc) Melanoma. , 2019, , 1-31.		0
89	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncology, The, 2018, 19, 451-460.	10.7	228
90	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist, 2018, 23, 540-555.	3.7	57

#	ARTICLE	IF	CITATIONS
91	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 405-415.	10.7	305
92	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , 2018, 24, 1805-1815.	7.0	45
93	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	1.6	156
94	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	1.6	2,691
95	Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. <i>Journal of Immunotherapy</i> , 2018, 41, 332-335.	2.4	68
96	Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis. <i>ACG Case Reports Journal</i> , 2018, 5, e17.	0.4	30
97	Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2018, 70, 127-137.	7.7	276
98	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
99	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	27.0	983
100	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	30.7	900
101	Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies â€” CPIT-001 Trial. <i>Blood</i> , 2018, 132, 256-256.	1.4	9
102	Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 3421-3421.	1.4	1
103	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4500-4500.	1.6	78
104	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	1.6	12
105	Clinical and economic outcomes associated with sequential treatment in <i>BRAF</i> mutant advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9538-9538.	1.6	4
106	Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9554-9554.	1.6	11
107	Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15074-e15074.	1.6	9
108	Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21609-e21609.	1.6	3

#	ARTICLE	IF	CITATIONS
109	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	1.6	164
110	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. <i>Journal of Clinical Oncology</i> , 2018, 36, 619-619.	1.6	2
111	Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence. <i>Blood</i> , 2018, 132, 3443-3443.	1.4	0
112	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	7.0	34
113	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3557-3565.	7.0	19
114	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
115	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. <i>Cancer Medicine</i> , 2017, 6, 1904-1914.	2.8	24
116	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	10.7	211
117	Indoor Tanning Dependence in Young Adult Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1636-1643.	2.5	56
118	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	1.6	244
119	The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. <i>Oncotarget</i> , 2017, 8, 12576-12595.	1.8	43
120	Characterization of tumor mutation load (TML) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11517-11517.	1.6	19
121	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4504-4504.	1.6	35
122	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4505-4505.	1.6	55
123	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4573-4573.	1.6	1
124	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9507-9507.	1.6	106
125	Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9522-9522.	1.6	6
126	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9545-9545.	1.6	10

#	ARTICLE	IF	CITATIONS
127	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. Journal of Clinical Oncology, 2017, 35, TPS4594-TPS4594.	1.6	15
128	Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, TPS4600-TPS4600.	1.6	2
129	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. Journal of Clinical Oncology, 2017, 35, 4576-4576.	1.6	0
130	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e505-e514.	3.8	10
131	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncology, The, 2016, 17, e542-e551.	10.7	1,274
132	Support for indoor tanning policies among young adult women who indoor tan. Translational Behavioral Medicine, 2016, 6, 613-621.	2.4	7
133	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
134	Phase 2 Study of Bevacizumab and Temezirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 304-313.e6.	1.9	11
135	Advances in immunotherapy for melanoma. BMC Medicine, 2016, 14, 20.	5.5	111
136	Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). International Journal of Radiation Oncology Biology Physics, 2016, 95, 632-646.	0.8	132
137	Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer, 2016, 122, 124-130.	4.1	43
138	Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). Expert Opinion on Emerging Drugs, 2016, 21, 243-254.	2.4	5
139	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 820-824.	4.9	36
140	Treatment of Melanoma CNS Metastases. Cancer Treatment and Research, 2016, 167, 263-279.	0.5	6
141	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. Journal of the National Cancer Institute, 2016, 108, djv414.	6.3	81
142	Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunology Research, 2016, 4, 419-430.	3.4	247
143	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 13.7 / Overlock 10 529		
144	Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma. , 2015, 3, .		18

#	ARTICLE	IF	CITATIONS
145	What's new in melanoma? Combination!. Journal of Translational Medicine, 2015, 13, 213.	4.4	38
146	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer, 2015, 121, 3435-3443.	4.1	64
147	Correlates of Sun Safety Practices in a Racially and Ethnically Diverse Sample of Adolescents: Implications for Skin Cancer Prevention Interventions. Pediatric Dermatology, 2015, 32, e288-90.	0.9	2
148	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	3.4	237
149	Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for BRAF-mutant melanoma: a case report. Melanoma Management, 2015, 2, 115-120.	0.5	4
150	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG-ACRIN Cancer Research Group (E2804). Journal of Clinical Oncology, 2015, 33, 2384-2391.	1.6	75
151	Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, 1873-1877.	1.6	9
152	Cancer Immunotherapy: Past Progress and Future Directions. Seminars in Oncology, 2015, 42, 518-522.	2.2	17
153	Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 2015, 33, 2092-2099.	1.6	521
154	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	1.6	385
155	The High-Dose Aldesleukin Select-Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 561-568.	7.0	133
156	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clinical Cancer Research, 2015, 21, 1925-1934.	7.0	67
157	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. Journal of Clinical Oncology, 2015, 33, 3431-3438.	1.6	49
158	Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clinical Cancer Research, 2015, 21, 4048-4054.	7.0	50
159	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network Cancer Research Group (E4697). Journal of Clinical Oncology, 2015, 33, 4066-4076.	1.6	101
160	Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. Seminars in Oncology, 2015, 42, S12-S19.	2.2	24
161	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International Immunology, 2015, 27, 39-46.	4.0	286
162	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. Journal of Clinical Oncology, 2015, 33, 3009-3009.	1.6	17

#	ARTICLE	IF	CITATIONS
163	Ipilimumab associated colitis: An IpiColitis case series at MedStar Georgetown University Hospital. World Journal of Gastroenterology, 2015, 21, 4373.	3.3	24
164	New Agents and New Targets for Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e222-e227.	3.8	26
165	High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. , 2014, 2, 26.		130
166	Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?. Clinical Cancer Research, 2014, 20, 2838-2845.	7.0	28
167	The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma. Translational Oncology, 2014, 7, 188-195.	3.7	40
168	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 2014, 120, 1695-1701.	4.1	195
169	Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Journal of Clinical Oncology, 2014, 32, 3771-3779.	1.6	99
170	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	1.6	2,015
171	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. Cancer Immunology Research, 2014, 2, 632-642.	3.4	512
172	Tumor Necrosis on Magnetic Resonance Imaging Correlates With Aggressive Histology and Disease Progression in Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 55-62.	1.9	34
173	Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1.) Tj ETQq1 1 0.784314 rgBT /Over of Clinical Oncology, 2014, 32, LBA9003-LBA9003.	1.6	51
174	Prognostic and predictive markers for the new immunotherapies. Oncology, 2014, 28 Suppl 3, 39-48.	0.5	68
175	Algorithm for the management of metastatic cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 32.	1.2	1
176	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 2013, 10, 588-598.	27.6	177
177	Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies. Clinical Pharmacology and Therapeutics, 2013, 95, 24-31.	4.7	75
178	<sc>PD</sc> as a potential target in cancer therapy. Cancer Medicine, 2013, 2, 662-673.	2.8	369
179	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 373-379.	1.6	199
180	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. Journal of Immunotherapy, 2012, 35, 66-72.	2.4	111

#	ARTICLE	IF	CITATIONS
181	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	27.0	10,727
182	Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4500-4500.	1.6	6
183	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4505-4505.	1.6	9
184	Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4606-4606.	1.6	5
185	Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8504-8504.	1.6	14
186	Predicting early relapse in patients with BRAF ^{V600E} melanoma with a highly sensitive blood BRAF assay.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8516-8516.	1.6	2
187	CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8527-8527.	1.6	1
188	Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8569-8569.	1.6	21
189	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA2509-CRA2509.	1.6	3
190	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA2509-CRA2509.	1.6	7
191	New Options and New Questions: How to Select and Sequence Therapies for Patients with Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 524-530.	3.8	3
192	Genetic polymorphisms influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4635-4635.	1.6	0
193	Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4543-4543.	1.6	0
194	Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression. <i>PLoS ONE</i> , 2011, 6, e19144.	2.5	64
195	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. <i>Clinical Cancer Research</i> , 2011, 17, 5443-5450.	7.0	164
196	Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2793-2802.	4.1	63
197	An Analysis of 1 year versus 3 month alpha-Interferon Treatment in Patients with Melanoma Stages IIB, IIC, and IIIA. <i>FASEB Journal</i> , 2010, 24, 954.5.	0.5	0
198	Does Arterial Spin-labeling MR Imaging measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?. <i>Radiology</i> , 2009, 251, 731-742.	7.3	111

#	ARTICLE	IF	CITATIONS
199	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799.	1.6	1,751
200	Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. <i>Cancer</i> , 2009, 115, 2247-2251.	4.1	24
201	Treatment selection for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2327-2333.	4.1	32
202	Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. <i>Medical Oncology</i> , 2009, 26, 18-22.	2.5	24
203	Everolimus. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 535-536.	46.4	74
204	Final Version of 2009 AJCC Melanoma Staging and Classification. <i>Journal of Clinical Oncology</i> , 2009, 27, 6199-6206.	1.6	4,126
205	Resistance to targeted therapy in renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2009, 10, 992-1000.	10.7	496
206	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. <i>Cancer</i> , 2008, 113, 2139-2145.	4.1	77
207	Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5748-5754.	1.6	292
208	Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 527-534.	1.6	634
209	Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. <i>Journal of Immunotherapy</i> , 2007, 30, 577-590.	2.4	2
210	Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference: Fig. 1.. <i>Clinical Cancer Research</i> , 2007, 13, 667s-670s.	7.0	36
211	Immunotherapy comes of age: overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 419-422.	3.1	0
212	The effect of recent drug approvals on translational research and drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 285-7.	0.3	0
213	Management of advanced renal cancer. <i>Kidney International</i> , 2005, 67, 2069-2082.	5.2	14
214	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	1.6	746
215	Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3714-3721.	7.0	401
216	Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 909-918.	1.6	948

#	ARTICLE	IF	CITATIONS
217	Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6342S-6346S.	7.0	133
218	Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2101-2107.	1.6	337
219	Innovations and Challenges in Renal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6277S-6281S.	7.0	38
220	The New Melanoma Staging System. <i>Cancer Control</i> , 2002, 9, 9-15.	1.8	123
221	Interleukin-2: Clinical applications. <i>Seminars in Oncology</i> , 2002, 29, 12-17.	2.2	116
222	A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2002, 8, 3075-81.	7.0	64
223	Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. <i>Journal of Clinical Oncology</i> , 2001, 19, 3622-3634.	1.6	2,394
224	Patient Preferences for Adjuvant Interferon Alfa-2b Treatment. <i>Journal of Clinical Oncology</i> , 2001, 19, 812-823.	1.6	85
225	A new American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Cancer</i> , 2000, 88, 1484-1491.	4.1	389
226	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999, 17, 2105-2105.	1.6	1,810
227	Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells. <i>New England Journal of Medicine</i> , 1988, 318, 1557-1563.	27.0	333
228	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. <i>Oncotarget</i> , 0, 7, 41857-41869.	1.8	21